Protocol Ledger

NCT03635099 · Phase II · COMPLETED

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Interventional Phase II clinical trial protocol NCT03635099 sponsored by Boehringer Ingelheim in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-17 Enrollment: 274 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03635099
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)274 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03635099
Protocol FieldVerified Registry Value
NCT IdentifierNCT03635099
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment274 participants (ACTUAL)
Registered Start Date2018-09-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03635099
Hospital Research SiteLocationSite Profile
Dermatology Research AssociatesLos Angeles, CAOpen Hospital Dossier ->
Dawes Fretzin Clinical Research Group, LLCIndianapolis, INOpen Hospital Dossier ->
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI